论文部分内容阅读
目的:应用改良疾病累计评分表(modified cumulative illness rating scale,MCIRS)评价合并症,观察晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者多西他赛联合顺铂化疗毒副反应发生率。方法:选择NSCLC患者60例,采用MCIRS评估合并症,根据MCIRS评分、年龄及KPS分层研究多西他赛联合顺铂化疗毒副反应发生率。结果:60例NSCLC患者MCIRS评分为2～20(9.250±3.917)分。其化疗毒副反应胃肠道反应、骨髓抑制、疲劳及脱发的发生率随MCIRS评分的升高而增高,差异具有统计学意义(P<0.05);随年龄增加和KPS评分降低而略增高,但无统计学意义(P>0.05)。结论:MCIRS能较好地评价晚期非小细胞肺癌患者合并症,化疗毒副反应发生率随MCIRS评分的升高而增高。
OBJECTIVE: To evaluate the comorbidity of patients with advanced non-small-cell lung cancer (NSCLC) by using the modified cumulative disease rating scale (MCIRS) and to observe the side effects of docetaxel plus cisplatin chemotherapy in patients with advanced non-small-cell lung cancer Occurrence rate. Methods: Sixty NSCLC patients were selected. MCIRS was used to evaluate the complication. The incidence of side effects of docetaxel and cisplatin chemotherapy was evaluated according to MCIRS score, age and KPS. Results: The MCIRS scores of 60 patients with NSCLC ranged from 2 to 20 (9.250 ± 3.917). The incidence of gastrointestinal reactions, myelosuppression, fatigue and alopecia were increased with the increase of MCIRS score (P <0.05), but slightly increased with age and KPS score. But not statistically significant (P> 0.05). Conclusion: MCIRS can better evaluate the patients with advanced non-small cell lung cancer complications, the incidence of chemotherapy toxicity increased with the MCIRS score increased.